BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 25142020)

  • 1. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation.
    Ren P; Yue M; Xiao D; Xiu R; Gan L; Liu H; Qing G
    J Pathol; 2015 Jan; 235(1):90-100. PubMed ID: 25142020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
    Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
    Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
    van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
    Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
    Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
    J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
    Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
    J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA
    Jiang J; Dong W; Zhang W; Wang Q; Wang R; Wang J; Wu H; Dong H; Zhao RC; Wang J; Li Z
    Discov Med; 2023 Dec; 35(179):995-1014. PubMed ID: 38058065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2.
    Xiao D; Ren P; Su H; Yue M; Xiu R; Hu Y; Liu H; Qing G
    Oncotarget; 2015 Dec; 6(38):40655-66. PubMed ID: 26528759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation.
    Le Grand M; Mukha A; Püschel J; Valli E; Kamili A; Vittorio O; Dubrovska A; Kavallaris M
    Theranostics; 2020; 10(14):6411-6429. PubMed ID: 32483461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence
    Ding M; Bu X; Li Z; Xu H; Feng L; Hu J; Wei X; Gao J; Tao Y; Cai B; Liu Y; Qu X; Shen L
    Int J Biol Sci; 2020; 16(16):3100-3115. PubMed ID: 33162818
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
    Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
    Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamine transporter ASCT2 was down-regulated in ischemic injured human intestinal epithelial cells and reversed by epidermal growth factor.
    Huang Q; Li N; Zhu W; Li Q; Li J
    JPEN J Parenter Enteral Nutr; 2007; 31(2):86-93. PubMed ID: 17308248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
    Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
    J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lobetyolin inhibits the proliferation of breast cancer cells
    Chen Y; Tian Y; Jin G; Cui Z; Guo W; Zhang X; Liu X
    Hum Exp Toxicol; 2021 Dec; 40(12):2074-2086. PubMed ID: 34075790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
    Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
    Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation.
    Qing G; Li B; Vu A; Skuli N; Walton ZE; Liu X; Mayes PA; Wise DR; Thompson CB; Maris JM; Hogarty MD; Simon MC
    Cancer Cell; 2012 Nov; 22(5):631-44. PubMed ID: 23153536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of glucose metabolism prevents glycosylation of the glutamine transporter ASCT2 and promotes compensatory LAT1 upregulation in leukemia cells.
    Polet F; Martherus R; Corbet C; Pinto A; Feron O
    Oncotarget; 2016 Jul; 7(29):46371-46383. PubMed ID: 27344174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter.
    Bungard CI; McGivan JD
    Biochem J; 2004 Aug; 382(Pt 1):27-32. PubMed ID: 15175006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting glutamine transport to suppress melanoma cell growth.
    Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
    Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.
    Qing G; Skuli N; Mayes PA; Pawel B; Martinez D; Maris JM; Simon MC
    Cancer Res; 2010 Dec; 70(24):10351-61. PubMed ID: 20961996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.